Loading…
Loading…
PKTX does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PKTX and 80,000+ other tickers.
See exactly how PKTX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PKTX and 80,000+ other tickers.
ProtoKinetix, Incorporated is a biotechnology firm engaged in research and development, specializing in the scientific and medical investigation of glycoproteins known as anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs). These AFGPs are particularly relevant for their commercial potential within the healthcare sector, with a key area of their development involving utilizing AAGPs for the treatment of dry-eye conditions. Their research efforts are bolstered by a collaborative agreement with the University of British Columbia. Originally incorporated in 1999 as RJV…
ProtoKinetix, Incorporated (OTCMKTS:PKTX - Get Free Report) shares crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $0.01 and traded as low as $0.0050. ProtoKinetix shares last traded at $0.0050, with a volume of 500 shares. ProtoKinetix Trading Down 16.7% The business's fifty
ProtoKinetix, Incorporated (OTCMKTS:PKTX - Get Free Report)'s stock price passed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $0.01 and traded as low as $0.0060. ProtoKinetix shares last traded at $0.0068, with a volume of 69,000 shares changing hands. ProtoKinetix Trading Up 13.3%
MARIETTA, Ohio--(BUSINESS WIRE)---- $PKTX #AMD--ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions